Rainer Strohmenger

HepaRegeniX GmbH is a clinical-stage biotechnology company developing novel therapies for the treatment of acute and chronic liver diseases.

Advanced Medical Balloons (AMB) is a specialized medical device company. The company develops and markets a novel catheter technology based on microscopically thin, complex-shaped balloon films made of polyurethane (PUR). AMB uses the properties of these extraordinary structures for problem-solving platform concepts in the fecal, urinary and respiratory segments. The current focus is on systems to contain patient contamination. In this context, Advanced Medical Balloons is developing a drainage technology for fecal management in intensive care patients that offers significant advantages in care, hygiene management and patient therapy. The first product of the fecal platform, hygh-tec, is already being used in the DACH region as a technology leader with great success. hygh-tec combines intelligent design with the exceptionally elastic properties of polyurethane. In fecal management, this catheter technology thus offers a uniquely tight access to the patients colon. This opens up new therapeutically oriented applications. In addition to contamination-free stool drainage, the trans-anal sealing mechanism of hygh-tec also enables an interventional, lavage-like delivery of substances into the colon. The company was founded in 2009 and is based in Waghäusel near Heidelberg, Germany. Imprint: https://amb-medtec.com/en/imprint.php

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

At Koa Health, we’ve made it our mission to leverage technology and research to create simple, personal, and accessible mental health support by combining evidence, cutting-edge tech, and user-centered design. We create breakthrough interventions backed by science with one clear goal: to improve people’s mental health. Designed to help your employees find the right mental healthcare at the right time, Koa Health’s comprehensive care model, Koa Care 360 offers employees simple navigation and personalized, evidence-based care built with the world’s leading clinician-academics. Koa Health provides an integrated approach to care that delivers mental health for everyone, whether they prefer digital-first care or would benefit from clinical services delivered by a human. Available to more than 3 million users worldwide, Koa Health addresses the full continuum of mental health needs – from prevention to treatment. Backed by leading investors such as Morningside, Ancora Finance Group, Wellington Partners Life Sciences, and MTIP, Koa Health leverages deep clinical expertise, research, and technology to deliver effective and accessible care that adapts to users’ unique circumstances, leading to lasting behavior change and positive health outcomes across the full continuum of mental health. Want to learn more about life at Koa Health? Visit our website at koahealth.com Our international team of behavioral scientists, developers, designers and health innovation leaders work, learn and grow together in a collaborative and inclusive culture. Want to learn more about life at Koa Health? Visit our website at koahealth.com

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Enibarcimab is a first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Enibarcimab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.

UroMems is a biotechnology company based out of 5, rue Raymond Chanas, 38320, Eybens, FRANCE

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development. Imprint: https://iomx.com/imprint

AMBOSS is a medical technology company with offices in New York, Berlin, Cologne and Cagliari. Its knowledge platform has fundamentally changed the way medical know-how is acquired and utilized at the point of care. Students use the interactive library and high-yield question bank for general study and exam preparation, while clinicians rely on AMBOSS to make effective clinical decisions guided by evidence-based recommendations. Founded in 2012 by physicians for physicians, the company’s international team has grown to over 400 physicians, scientists and software engineers, all striving to better serve physicians around the world. Today, more than a million healthcare professionals in over 180 countries rely on AMBOSS. Privacy Policy: https://www.amboss.com/us/privacy Terms of Conditions: https://www.amboss.com/us/terms German Datenschutzrichtlinien: https://www.amboss.com/de/de-legal/datenschutz-uebersicht German Impressum: https://www.amboss.com/de/impressum

AMBOSS is a medical technology company with offices in New York, Berlin, Cologne and Cagliari. Its knowledge platform has fundamentally changed the way medical know-how is acquired and utilized at the point of care. Students use the interactive library and high-yield question bank for general study and exam preparation, while clinicians rely on AMBOSS to make effective clinical decisions guided by evidence-based recommendations. Founded in 2012 by physicians for physicians, the company’s international team has grown to over 400 physicians, scientists and software engineers, all striving to better serve physicians around the world. Today, more than a million healthcare professionals in over 180 countries rely on AMBOSS. Privacy Policy: https://www.amboss.com/us/privacy Terms of Conditions: https://www.amboss.com/us/terms German Datenschutzrichtlinien: https://www.amboss.com/de/de-legal/datenschutz-uebersicht German Impressum: https://www.amboss.com/de/impressum

Quanta Dialysis Technologies is committed to making dialysis accessible to every patient in every setting with its SC+ hemodialysis system. As a portable device with performance comparable to larger, traditional machines, SC+ is a modular and powerful solution that provides the clinical versatility needed to deliver dialysis care across multiple settings. With a simple-to-use and intuitive user interface, SC+ is designed to be operated by a broad range of users to bring dialysis directly to patients. Disclaimer: The SC+ Haemodialysis system is FDA-cleared for use on patients with acute and/or chronic renal failure when administered by a trained person in an acute or chronic care facility. It is not indicated for home or nocturnal use in the USA. CONTACT US Office / Business Enquiries: UK: 0-178-940-0043 US: 1-978-483-0669 Customer Care: UK: 0-808-164-2640 US: 1-800-590-1393

Oxford Immunotec is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company's T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. http://www.oxfordimmunotec.com/north-america/wp-content/uploads/sites/2/Disclaimer-V2.pdf

Based near Bordeaux (FR), IMPLANET is an international company with a US subsidiary in Boston, funded by European institutional and private investors. IMPLANET focuses on spine and knee products. Its flagship product, the Jazz™ latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, Jazz™ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Taking into account the evolution of the global healthcare system, the IMPLANET Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The IMPLANET R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation. Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals. IMPLANET is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Twitter: https://twitter.com/immatics Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/

NoemaLife is an International Group established 1996 in Italy, listed on the Italian Stock Exchange since 2006, now a leading European name in the clinical and hospital information systems market. Intended for both public and private healthcare organizations, NoemaLife software solutions help to make the Healthcare System more efficient, by reducing costs and improving the quality of the patient care process. NoemaLife solutions optimize the workflow of healthcare structures at departmental, hospital and regional level, through the adoption of a new management approach. Operating with a staff of 750 professionals worldwide, NoemaLife maintains a direct market presence in Italy, France, Germany, United Kingdom, Argentina, Chile, Belgium, Japan, the United Arab Emirates, Mexico, Balcan Area, Morocco and Algeria. The Group collaborates with top Universities and with the world's finest Research Centres, taking an active part in many International and European Projects. In 2011 NoemaLife acquired the majority capital shareholding in the French Company Medasys — a brand leader in France, listed on the Paris Stock Exchange — thereby consolidating its role as the premier provider of IT solutions for clinical processes across Europe. In June 2016 Dedalus S.p.A. acquired the majority of NoemaLife S.p.A.. The joining of the two international organisations, marked the birth of the first operator in Italy, with a widespread presence throughout the national territory, and among the first players in Europe, with a revenue target for 2016 of about 170 million euro and with more than 1.700 healthcare professionals of which 1.100 in Italy. The new group is active with its subsidiaries in France, Spain, UK, USA, Latin America, China, Middle East and North and South Africa.

HepaRegeniX GmbH is a clinical-stage biotechnology company developing novel therapies for the treatment of acute and chronic liver diseases.

Advanced Medical Balloons (AMB) is a specialized medical device company. The company develops and markets a novel catheter technology based on microscopically thin, complex-shaped balloon films made of polyurethane (PUR). AMB uses the properties of these extraordinary structures for problem-solving platform concepts in the fecal, urinary and respiratory segments. The current focus is on systems to contain patient contamination. In this context, Advanced Medical Balloons is developing a drainage technology for fecal management in intensive care patients that offers significant advantages in care, hygiene management and patient therapy. The first product of the fecal platform, hygh-tec, is already being used in the DACH region as a technology leader with great success. hygh-tec combines intelligent design with the exceptionally elastic properties of polyurethane. In fecal management, this catheter technology thus offers a uniquely tight access to the patients colon. This opens up new therapeutically oriented applications. In addition to contamination-free stool drainage, the trans-anal sealing mechanism of hygh-tec also enables an interventional, lavage-like delivery of substances into the colon. The company was founded in 2009 and is based in Waghäusel near Heidelberg, Germany. Imprint: https://amb-medtec.com/en/imprint.php

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

At Koa Health, we’ve made it our mission to leverage technology and research to create simple, personal, and accessible mental health support by combining evidence, cutting-edge tech, and user-centered design. We create breakthrough interventions backed by science with one clear goal: to improve people’s mental health. Designed to help your employees find the right mental healthcare at the right time, Koa Health’s comprehensive care model, Koa Care 360 offers employees simple navigation and personalized, evidence-based care built with the world’s leading clinician-academics. Koa Health provides an integrated approach to care that delivers mental health for everyone, whether they prefer digital-first care or would benefit from clinical services delivered by a human. Available to more than 3 million users worldwide, Koa Health addresses the full continuum of mental health needs – from prevention to treatment. Backed by leading investors such as Morningside, Ancora Finance Group, Wellington Partners Life Sciences, and MTIP, Koa Health leverages deep clinical expertise, research, and technology to deliver effective and accessible care that adapts to users’ unique circumstances, leading to lasting behavior change and positive health outcomes across the full continuum of mental health. Want to learn more about life at Koa Health? Visit our website at koahealth.com Our international team of behavioral scientists, developers, designers and health innovation leaders work, learn and grow together in a collaborative and inclusive culture. Want to learn more about life at Koa Health? Visit our website at koahealth.com

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.